To identify immunotherapy biomarkers, we examined granzyme B levels in peripheral blood PD-1+ CD8+ T cells and their relationship with treatment outcomes in patients with non-small cell lung cancer (NSCLC).

Interaction analysis between granzyme B, expression of PD-L1 in tumor and TMB showed that these markers were not intercorrelated, which suggests their value as independent biomarkers for clinical outcome after PD-1 ICIs.

Hence, in this study we aimed to assess the association of baseline serum granzyme B, as well as germline variation of the GZMB gene, with clinical outcome to programmed cell death protein 1 (PD-1) blockade.

Our data demonstrate that granzyme B is an important player in the antitumor immunity, as a consequence of the finding that low serum levels of granzyme B and germline variation of the GZMB gene contributes to resistance to PD-1 blockade in advanced NSCLC. As recent clinical trial results underline effective biomarker-based patient selection ...

Nov 28, 2023 · PD-1 blockade or genetic ablation in aged mice yielded improved CD8 + T cell granzyme B production comparable to that in young mice during human metapneumovirus and influenza viral infections.

Results: We found that the sequential change of granzyme B+ T cells after immunotherapy (t1/t0) significantly predicted durable clinical benefit (DCB) compared to no clinical benefit (NCB) (P=0.048), and prolonged PFS (P=0.025).

Nov 1, 2023 · PD-1 blockade of aged mice during rechallenge infection resulted in improved clinical outcomes that paralleled reduced accumulation of CD8+ TRM cells. These findings suggest that PD-1 signaling impaired CD8+ T cell granzyme B production and contributed to CD8+ TRM cell accumulation in the aged lung.

Oct 2, 2020 · In this study, we designed a granzyme B (GrB) nanoreporter (GNR) that can deliver an immune checkpoint inhibitor to the tumor and track time-sensitive GrB activity as a direct way to monitor initiation of effective immune responses.

Hence, in this study we aimed to assess the association of baseline serum granzyme B, as well as germline variation of the GZMB gene, with clinical outcome to programmed cell death protein 1 (PD-1) blockade.

May 1, 2020 · Hence, in this study we aimed to assess the association of baseline serum granzyme B, as well as germline variation of the GZMB gene, with clinical outcome to programmed cell death protein 1...